Inflammatory bowel disease (IBD) diagnosis appears to be associated with high levels of anxiety and depression in children, however, new study findings presented at the 2019 AIBD Annual Meeting suggest that many of these patients may not be receiving appropriate mental health services.
The Food and Drug Administration (FDA) has accepted for filing the supplemental Biologics License Application (sBLA) for omalizumab (Genentech) for the treatment of adults with chronic rhinosinusitis with nasal polyps who have had an inadequate response to intranasal corticosteroids. The sBLA includes data from the POLYP 1 and POLYP 2 trials, which showed that treatment…
The prefilled syringe requires fewer preparation steps than the vial.
The FDA has granted Fast Track designation to PH94B (aloradine; VistaGen Therapeutics), a central nervous system neuroactive nasal spray for the on-demand treatment of social anxiety disorder.
Over 1400 clinical trials and research studies were reviewed by a panel of 13 experts to develop the new guideline.
To investigate the association between this diabetes drug class and IBD risk, the study authors searched various databases for controlled clinical trials and observational studies involving DPP-4 inhibitors where IBD events were reported.
Currently, there are no approved therapies for the treatment of MSA, a rare progressive neurodegenerative disease.
Tolsura, which contains the azole antifungal itraconazole, is formulated using the Company’s proprietary SUBA (SUper-BioAvailable) technology which improves the bioavailability of poorly soluble drugs.
Phase 3 studies investigating safety, tolerability, and immunogenicity in both adults and children are currently underway.
The procedure, known as Elevoplasty, was investigated in the S.I.L.E.N.C.E. study (Snoring Intervention via Elevoplasty in a Non-surgical Clinical Environment) which included 52 patients.
